SynthesisFrontiers in medicine2025
The efficacy and safety of spesolimab in patients with generalized pustular psoriasis flares: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical Practice Recommendations for Non-Dermatologists on the Diagnostic Suspicion of GPP.Journal of clinical medicine · 2026Review
- IL-36-Driven Inflammation in Generalized Pustular Psoriasis: Immunological Insights from Plaque Psoriasis and Implications for Targeted Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Generalized pustular psoriasis (GPP) is a rare, auto-inflammatory skin disease characterized by unpredictable flares, often requiring hospitalization, and current therapies lack robust evidence. Objectives: To systematically evaluate the efficacy and safety of spesolimab for acute GPP flares. Methods: We searched Medline, Google Scholar and the Cochrane Central Register of Controlled Trials from inception to December 2024 and consulted ClinicalTrials.gov and the ISRCTN registry for ongoing studies. Randomized controlled trials enrolling adults experiencing GPP flares and comparing spesolimab with placebo or standard care were eligible. Non-randomized studies, studies without placebo comparators, or without full-text availability were excluded. Two reviewers independently assessed risk of bias using the Cochrane RoB 2 tool and extracted data. A random-effects model was used to pool odds ratios or mean differences with 95% confidence intervals. Results: Four randomized controlled trials with 176 participants met the inclusion criteria. Compared with placebo, spesolimab significantly increased the proportion of patients achieving complete pustular clearance [GPPGA pustulation score 0; OR 4.87 (95% CI 2.03-11.68)] and a total GPPGA score of 0 or 1 [OR 5.68 (95% CI 2.27-14.23)]. Adverse event rates were similar between groups and were mostly mild or moderate. Limitations: Evidence was limited by the small number and sample size of trials, heterogeneity between studies and short follow-up durations. Conclusion: Spesolimab provides clinically meaningful improvements in pustular clearance and symptom control during acute GPP flares and has a favorable safety profile; however, further large, long-term randomized trials are needed. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025629994, identifier CRD42025629994.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.